MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Danaher Corp

Closed

SectorHealthcare

196.46 -0.12

Overview

Share price change

24h

Current

Min

192.46

Max

196.82

Key metrics

By Trading Economics

Income

268M

1.1B

Sales

738M

6.5B

P/E

Sector Avg

34.964

57.333

EPS

2.14

Dividend yield

0.69

Profit margin

16.611

Employees

61,000

EBITDA

-230M

1.4B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+22.87% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.69%

2.63%

Next Earnings

22 Jul 2025

Next Dividend date

25 Apr 2025

Market Stats

By TradingEconomics

Market Cap

-29B

134B

Previous open

196.58

Previous close

196.46

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Danaher Corp Chart

Past performance is not a reliable indicator of future results.

Related News

22 Apr 2025, 10:34 UTC

Earnings

Danaher 1Q Results Decline But Top Estimates

5 Feb 2025, 12:54 UTC

Earnings

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 Jan 2025, 11:44 UTC

Earnings

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 Oct 2024, 10:35 UTC

Earnings

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

22 Apr 2025, 10:02 UTC

Earnings

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 Apr 2025, 10:02 UTC

Earnings

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 Apr 2025, 10:02 UTC

Earnings

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 Apr 2025, 10:01 UTC

Earnings

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 Apr 2025, 10:01 UTC

Earnings

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 Apr 2025, 10:00 UTC

Earnings

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22 Apr 2025, 10:00 UTC

Earnings

Danaher 1Q Adj EPS $1.88 >DHR

22 Apr 2025, 10:00 UTC

Earnings

Danaher 1Q EPS $1.32 >DHR

22 Apr 2025, 10:00 UTC

Earnings

Danaher 1Q Sales $5.74B >DHR

22 Apr 2025, 10:00 UTC

Earnings

Danaher 1Q Net $954M >DHR

29 Jan 2025, 15:25 UTC

Market Talk
Earnings

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 Jan 2025, 13:56 UTC

Top News
Earnings

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 Jan 2025, 11:08 UTC

Earnings

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 Jan 2025, 11:07 UTC

Earnings

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 Jan 2025, 11:07 UTC

Earnings

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 Jan 2025, 11:02 UTC

Earnings

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 Jan 2025, 11:01 UTC

Earnings

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 Jan 2025, 11:01 UTC

Earnings

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Net $1.09B >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q EPS $1.49 >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Adj EPS $2.14 >DHR

29 Jan 2025, 11:00 UTC

Earnings

Danaher 4Q Sales $6.5B >DHR

22 Oct 2024, 10:02 UTC

Earnings

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 Oct 2024, 10:02 UTC

Earnings

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Peer Comparison

Price change

Danaher Corp Forecast

Price Target

By TipRanks

22.87% upside

12 Months Forecast

Average 241.2 USD  22.87%

High 265 USD

Low 210 USD

Based on 18 Wall Street analysts offering 12 month price targets forDanaher Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

15

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

190.1 / 199.64Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.